| __timestamp | Catalent, Inc. | Gilead Sciences, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 334800000 | 2983000000 |
| Thursday, January 1, 2015 | 337300000 | 3426000000 |
| Friday, January 1, 2016 | 358100000 | 3398000000 |
| Sunday, January 1, 2017 | 402600000 | 3878000000 |
| Monday, January 1, 2018 | 462600000 | 4056000000 |
| Tuesday, January 1, 2019 | 512000000 | 4381000000 |
| Wednesday, January 1, 2020 | 577900000 | 5151000000 |
| Friday, January 1, 2021 | 687000000 | 5246000000 |
| Saturday, January 1, 2022 | 844000000 | 5673000000 |
| Sunday, January 1, 2023 | 831000000 | 6090000000 |
| Monday, January 1, 2024 | 935000000 |
Unleashing the power of data
In the competitive landscape of the pharmaceutical and biotechnology sectors, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. Gilead Sciences, Inc. and Catalent, Inc. have taken different paths in optimizing these costs over the past decade.
From 2014 to 2023, Catalent, Inc. has seen a steady increase in SG&A expenses, rising from approximately $334 million to $831 million, marking a growth of about 149%. In contrast, Gilead Sciences, Inc. experienced a 104% increase, from $2.98 billion to $6.09 billion over the same period.
While Gilead's expenses are significantly higher, the growth rate is more moderate compared to Catalent. This suggests that Gilead may have a more stable approach to managing these costs, despite the larger absolute figures. However, the absence of data for Gilead in 2024 leaves room for speculation on future trends.
Comparing SG&A Expenses: Novartis AG vs Gilead Sciences, Inc. Trends and Insights
Operational Costs Compared: SG&A Analysis of Gilead Sciences, Inc. and Vertex Pharmaceuticals Incorporated
Gilead Sciences, Inc. vs Alnylam Pharmaceuticals, Inc.: SG&A Expense Trends
Selling, General, and Administrative Costs: Gilead Sciences, Inc. vs Regeneron Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing Gilead Sciences, Inc. and CRISPR Therapeutics AG
Comparing SG&A Expenses: Gilead Sciences, Inc. vs Galapagos NV Trends and Insights
Breaking Down SG&A Expenses: Gilead Sciences, Inc. vs BioCryst Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? Insmed Incorporated or Catalent, Inc.
Cost Management Insights: SG&A Expenses for BioMarin Pharmaceutical Inc. and Catalent, Inc.
SG&A Efficiency Analysis: Comparing Catalent, Inc. and Verona Pharma plc
Comparing SG&A Expenses: Catalent, Inc. vs Viking Therapeutics, Inc. Trends and Insights
Operational Costs Compared: SG&A Analysis of Catalent, Inc. and Soleno Therapeutics, Inc.